Travere Therapeutics, Inc. (TVTX)

6,30 -0,30 (-4,55%) Alla chiusura: 04:00PM EDT

Travere Therapeutics, Inc.

3611 Valley Centre Drive
Suite 300
San Diego, CA 92130
United States
888 969 7879
https://www.travere.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 380

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Eric M. Dube Ph.D.	President, CEO & Director	1,4M	N/D	1973
Mr. Christopher Cline C.F.A.	Chief Financial Officer	709,94k	N/D	1985
Ms. Elizabeth E. Reed J.D.	Senior VP, General Counsel & Corporate Secretary	713,63k	N/D	1971
Dr. William E. Rote Ph.D.	Senior VP and Head of Research & Development	748,02k	N/D	1963
Mr. Peter Heerma	Chief Commercial Officer	742,37k	N/D	1972
Ms. Sandra Calvin	SVP, Corporate Controller & Chief Accounting Officer	N/D	N/D	1966
Ms. Naomi Eichenbaum	Vice President of Investor Relations	N/D	N/D	N/D
Ms. Charlotte Smith	Senior Vice President of Public Affairs	N/D	N/D	N/D
Ms. Angela Giannantonio	Senior Vice President of Human Resources	N/D	N/D	N/D
Mr. Casey Logan	Chief Business Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Travere Therapeutics, Inc. al 1 maggio 2024 è 4. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.